Publications
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling
Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates
Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates
Detection of a novel GNA11 processed pseudogene in chromosome 20 from cfDNA and implications for liquid biopsy
Detection of a novel GNA11 processed pseudogene in chromosome 20 from cfDNA and implications for liquid biopsy
Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay
Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay
Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
Clinical Validation of the Northstar Response: A Novel Quantitative Methylation ctDNA Monitoring Assay for Advanced GI Cancer Treatment Response
Clinical Validation of the Northstar Response: A Novel Quantitative Methylation ctDNA Monitoring Assay for Advanced GI Cancer Treatment Response
Absolute quantification of cell-free DNA for prenatal genetics and oncology
Absolute quantification of cell-free DNA for prenatal genetics and oncology
Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC
Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC
Methylation-Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in NSCLC
Methylation-Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in NSCLC
A novel liquid biopsy assay with an 88% detection rate of genomic alterations across CNS tumors.
A novel liquid biopsy assay with an 88% detection rate of genomic alterations across CNS tumors.
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
Analytical and clinical validity of Northstar Select, a quantitatively enhanced liquid biopsy assay for comprehensive genomic profiling of solid tumors
Analytical and clinical validity of Northstar Select, a quantitatively enhanced liquid biopsy assay for comprehensive genomic profiling of solid tumors
Clinical Validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay in patients with advanced GI cancer undergoing active treatment
Clinical Validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay in patients with advanced GI cancer undergoing active treatment
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.
